The safety profile of dual agonists is similar to pure GLP-1 agonists, with the main difference being slightly higher rates of GI side effects
So this is now looking at a much larger database and looking at two drugs, they're looking at a drug called Sexenda (liraglutide), which is a much older drug than Ozempic or semaglutide, and they are looking at semaglutide
Yes LipoMax RF is one of the strongest revenue-generating devices available for aesthetic practices, with partner centers reporting $20,000$30,000 in monthly revenue per treatment room
They also protect a different set of claims, meaning a generic manufacturer that synthesizes the identical molecule cannot automatically use the branded delivery system without potential infringement
doi:10.1039/c5fo01530h [9] Ma J, Guo CY, Li HB, Wu SH, Li GL
I pray I don't get desperate enough to consider self-compounding peptides in my home